

Press Release

Changes of Representative Director and Directors

TOKYO, April 27, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at a meeting of its Board of Directors held today, it decided changes of Representative Director and Directors as stated below. These changes are subject to approval at the 18th Term Annual Shareholders Meeting and decision at the Board of Directors meeting, both scheduled on June 22, 2023.

1. Change of Representative Director

- New Representative Director Candidate

Katsuyoshi Sugita

(New) Representative Director, Executive Vice President *

* He continues to serve as Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO).

(Current) Senior Corporate Executive (Senmu Tantou-Yakuin)

Chief People Officer and Chief Ethics & Compliance Officer

- Effective date of change: June 22, 2023
- Reason for change: This change is decided in order to pursue Astellas' growth strategies more vigorously with the new leader.

**2. Candidates for Directors
(Excluding Directors who are Audit & Supervisory Committee Members)**

Name		Current Position
Kenji Yasukawa	Reelection	Representative Director, Chairman of the Board
Naoki Okamura	Reelection	Representative Director, President and CEO
Katsuyoshi Sugita	New Candidate	Senior Corporate Executive (Senmu Tantou-Yakuin) Chief People Officer and Chief Ethics & Compliance Officer
Takashi Tanaka	Outside Reelection	Representative Director, Chairman of the Board, KDDI CORPORATION Director, Okinawa Cellular Telephone Company
Eriko Sakurai	Outside Reelection	Outside Director, Sumitomo Mitsui Financial Group, Inc. Outside Director, Kao Corporation
Masahiro Miyazaki	Outside New Candidate	Outside Director, Kurita Water Industries Ltd.
Yoichi Ohno	Outside New Candidate	Visiting Professor, Social Medicine, Research Administration Center and Medical Education Center, Saitama Medical University

The current position of the candidates for outside Directors describes significant concurrent positions at other organizations pursuant to the Companies Act.

3. Candidates for Directors who are Audit & Supervisory Committee Members

Name		Current Position
Rie Akiyama	Outside New Candidate	Baba & Sawada Law Office Outside Director, GOLDWIN INC.

The current position of the candidate for outside Director describes significant concurrent positions at other organizations pursuant to the Companies Act.

4. Directors to be retired

Outside Director	Mamoru Sekiyama
Outside Director	Hiroshi Kawabe
Outside Director, Audit & Supervisory Committee Member	Haruko Shibumura

5. The Board of Directors as from June 22, 2023 (planned)

Kenji Yasukawa (Representative Director, Chairman of the Board)

Naoki Okamura (Representative Director, President and CEO)

Katsuyoshi Sugita (Representative Director, Executive Vice President)

Takashi Tanaka (Outside Director)

Eriko Sakurai (Outside Director)

Masahiro Miyazaki (Outside Director)

Yoichi Ohno (Outside Director)

Toru Yoshimitsu (Director, Audit & Supervisory Committee Member)

Raita Takahashi (Outside Director, Audit & Supervisory Committee Member)

Mika Nakayama (Outside Director, Audit & Supervisory Committee Member)

Rie Akiyama (Outside Director, Audit & Supervisory Committee Member)

(Reference)

Name: Katsuyoshi Sugita

Date of birth: September 3, 1967

Number of shares of the Company owned: 1,100 shares

Resume, position and responsibilities at the Company:

April 1991	Joined Asahi Kasei Corp.
January 2005	Director, Human Resources, Medical Devices, Johnson & Johnson K.K.
November 2008	Vice President, Human Resources, Hilti Japan Ltd.
August 2012	Vice President, Human Resources, AstraZeneca K.K.
July 2016	Senior Director, Human Resources, Microsoft Japan Co., Ltd.
May 2021	Executive Vice President, Human Resources, the Company (present post)
October 2022	Corporate Executive, Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO), the Company (present post)

Name: Masahiro Miyazaki

Date of birth: April 13, 1954

Resume, position and responsibilities at the Company:

April 1977	Joined Nissei Sangyo Co., Ltd. (current Hitachi High-Tech Corporation)
March 1990	Chief Representative, Kuala Lumpur Representative Office, Nissei Sangyo (Singapore) Pte. Ltd. (current Hitachi High-Tech (Singapore) Pte. Ltd.)
January 1995	General Manager, Electronic Components Div., Nissei Sangyo America, Ltd. (current Hitachi High-Tech America, Inc.)
June 2002	Deputy General Manager, Electronics Div., Hitachi High-Technologies Corporation (current Hitachi High-Tech Corporation)
July 2004	General Manager, Electronics Div., Hitachi High-Technologies Corporation (current Hitachi High-Tech Corporation)
April 2007	Executive Officer, General Manager, Regional Branch Office for West Japan Area and Kansai Branch Office, Hitachi High- Technologies Corporation (current Hitachi High-Tech Corporation)
April 2010	President & CEO, Hitachi High-Technologies America, Inc. (current Hitachi High-Tech America, Inc.)

April 2014	Senior Vice President and Executive Officer, General Manager, Corporate Strategy Div., Fine Technology Systems Business Div. and CSO (Chief Strategy Officer), Hitachi High-Technologies Corporation (current Hitachi High-Tech Corporation)
April 2015	Representative Executive Officer, President and Chief Executive Officer, Hitachi High-Technologies Corporation (current Hitachi High-Tech Corporation)
June 2015	Representative Executive Officer, President and Chief Executive Officer and Director., Hitachi High-Technologies Corporation (current Hitachi High-Tech Corporation)
April 2021	Chairman Emeritus, Hitachi High-Tech Corporation
June 2022	Outside Director, Kurita Water Industries Ltd. (present post)

Name: Yoichi Ohno

Date of birth: July 17, 1961

Resume, position and responsibilities at the Company:

May 1993	Assistant Professor, Internal Medicine, School of Medicine, Keio University
April 1995	Deputy Chief, Internal Medicine, Tokyo Denryoku Hospital
April 2002	Director, Green Town Clinic Center, and Chief, Internal Medicine, Green Town Clinic
July 2005	Chief, Nephrology, Endocrinology and Metabolism Department, Internal Medicine, Saitama City Hospital
April 2007	Senior Lecturer, Nephrology, Saitama Medical University
August 2007	Senior Lecturer, Community Health Science Center, Saitama Medical University
April 2013	Associate Professor, Community Health Science Center and Nephrology, Saitama Medical University
April 2020	Visiting Professor, Social Medicine, Research Administration Center and Medical Education Center, Saitama Medical University (present post)

Name: Rie Akiyama

Date of birth: March 17, 1970

Resume, position and responsibilities at the Company:

April 1992	Joined Sanwa Bank Ltd. (current MUFG Bank, Ltd.)
April 1999	Registered as attorney-at-law (Tokyo Bar Association)
April 1999	Joined Baba Law Office (current Baba & Sawada Law Office)

June 2019 (present post)
Outside Director, GOLDWIN INC. (present post)

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+[®] healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
+81-3-3244-3201